Product Name :
Tanomastat
Description:
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models.
CAS:
179545-77-8
Molecular Weight:
410.91
Formula:
C23H19ClO3S
Chemical Name:
(2S)-4-4′-chloro-[1,1′-biphenyl]-4-yl-4-oxo-2-[(phenylsulfanyl)methyl]butanoic acid
Smiles :
OC(=O)[C@H](CC(=O)C1C=CC(=CC=1)C1C=CC(Cl)=CC=1)CSC1C=CC=CC=1
InChiKey:
JXAGDPXECXQWBC-LJQANCHMSA-N
InChi :
InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models.|Product information|CAS Number: 179545-77-8|Molecular Weight: 410.91|Formula: C23H19ClO3S|Synonym:|BAY 12-9566|Chemical Name: (2S)-4-4′-chloro-[1,1′-biphenyl]-4-yl-4-oxo-2-[(phenylsulfanyl)methyl]butanoic acid|Smiles: OC(=O)[C@H](CC(=O)C1C=CC(=CC=1)C1C=CC(Cl)=CC=1)CSC1C=CC=CC=1|InChiKey: JXAGDPXECXQWBC-LJQANCHMSA-N|InChi: InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Mirvetuximab soravtansine (solution) web |Shelf Life: ≥12 months if stored properly.Litifilimab medchemexpress |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:32463711 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Tanomastat (BAY 12-9566) (1-10000 nM; 6 hours) prevents matrix invasion by endothelial cells in a concentration-dependent manner (IC50=840 nM), without affecting cell proliferation. Tanomastat (BAY 12-9566) (1-00 µM; 5 days) inhibits tubule formation completely at 15-100 µM.|In Vivo:|Tanomastat (BAY 12-9566) (100 mg/kg; p.o.; daily for a 7-week period) inhibits local tumor regrowth without causing any toxic effect, and inhibits the number and volume of lung metastases.|References:|Leung D, et al. Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.Gatto C, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999 Nov;5(11):3603-7.Nozaki S, et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancerorthotopic model. Clin Exp Metastasis. 2003;20(5):407-12.Products are for research use only. Not for human use.|